MA54530B1 - Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques - Google Patents
Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiquesInfo
- Publication number
- MA54530B1 MA54530B1 MA54530A MA54530A MA54530B1 MA 54530 B1 MA54530 B1 MA 54530B1 MA 54530 A MA54530 A MA 54530A MA 54530 A MA54530 A MA 54530A MA 54530 B1 MA54530 B1 MA 54530B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- treatment
- nervous system
- central nervous
- dopaminergic
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title abstract 3
- 230000003291 dopaminomimetic effect Effects 0.000 title abstract 3
- XHCSBQBBGNQINS-DOTOQJQBSA-N 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone Chemical compound N1([C@H](C2=CC=CC(CCC(C)(C)O)=C2C[C@@H]1CO)C)C(=O)CC1=C(Cl)C=CC=C1Cl XHCSBQBBGNQINS-DOTOQJQBSA-N 0.000 abstract 2
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 2
- 201000002832 Lewy body dementia Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002942 Apathy Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 abstract 1
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- 206010024264 Lethargy Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010041349 Somnolence Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 235000021229 appetite regulation Nutrition 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000017004 dementia pugilistica Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000033914 shift work type circadian rhythm sleep disease Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des schémas posologiques et des procédés d'utilisation de LY3154207, également décrit en tant que 2-(2,6-dichlorophényl)-1-[(1S,3R)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl-3,4-dihydroisoquinoline-2(1H)-yl]éthanone, et/ou des compositions pharmaceutiques de ceux-ci, pour le traitement de troubles du système nerveux central dopaminergiques. Les troubles du SNC dopaminergiques des présents procédés de schémas posologiques comprennent la maladie de Parkinson, la maladie d'Alzheimer, la démence à corps de Lewy (LBD), la démence vasculaire, la schizophrénie, le trouble du déficit de l'attention/hyperactivité, la dépression, l'autisme, la douleur musculo-squelettique chronique, la fibromyalgie, les troubles liés à la déficience cognitive, les troubles du sommeil, la somnolence diurne excessive, la narcolepsie, le trouble lié au travail par roulement, le traumatisme craniocérébral, l'encéphalopathie traumatique chronique, l'obésité et la régulation de l'appétit, les troubles de l'humeur, la léthargie, l'apathie et les troubles de la dépendance.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781251P | 2018-12-18 | 2018-12-18 | |
| US201962904048P | 2019-09-23 | 2019-09-23 | |
| PCT/US2019/066465 WO2020131671A1 (fr) | 2018-12-18 | 2019-12-16 | Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques |
| EP19836884.7A EP3897578B1 (fr) | 2018-12-18 | 2019-12-16 | Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54530A MA54530A (fr) | 2021-10-27 |
| MA54530B1 true MA54530B1 (fr) | 2025-02-28 |
Family
ID=69167914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71651A MA71651A (fr) | 2018-12-18 | 2019-12-16 | Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques |
| MA54530A MA54530B1 (fr) | 2018-12-18 | 2019-12-16 | Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71651A MA71651A (fr) | 2018-12-18 | 2019-12-16 | Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20220062265A1 (fr) |
| EP (2) | EP4417258A3 (fr) |
| JP (4) | JP2022514659A (fr) |
| KR (2) | KR20210111783A (fr) |
| CN (1) | CN113347961A (fr) |
| AU (1) | AU2019402087B2 (fr) |
| BR (1) | BR112021012102A2 (fr) |
| CA (1) | CA3124416C (fr) |
| DK (1) | DK3897578T3 (fr) |
| ES (1) | ES3004543T3 (fr) |
| FI (1) | FI3897578T3 (fr) |
| HR (1) | HRP20241778T1 (fr) |
| HU (1) | HUE069782T2 (fr) |
| IL (1) | IL284175A (fr) |
| LT (1) | LT3897578T (fr) |
| MA (2) | MA71651A (fr) |
| MD (1) | MD3897578T2 (fr) |
| MX (1) | MX2021007442A (fr) |
| MY (1) | MY209406A (fr) |
| PL (1) | PL3897578T3 (fr) |
| PT (1) | PT3897578T (fr) |
| RS (1) | RS66337B1 (fr) |
| SG (1) | SG11202106595VA (fr) |
| SI (1) | SI3897578T1 (fr) |
| TW (2) | TWI831896B (fr) |
| UA (1) | UA126882C2 (fr) |
| WO (1) | WO2020131671A1 (fr) |
| ZA (1) | ZA202104466B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4200280T3 (pl) * | 2020-10-07 | 2024-05-20 | Eli Lilly And Company | Pochodne fenylo-3,4-dihydroizochinolin-2(1h)-ylo-etan-1-onu jako dodatnie modulatory allosteryczne receptora dopaminy d1 |
| JP7824310B2 (ja) * | 2021-03-08 | 2026-03-04 | イーライ リリー アンド カンパニー | 幻覚及び認知症に関連する精神病の治療におけるメビダレン及び他のｄ１陽性アロステリックモジュレーターの使用 |
| JP2024509272A (ja) * | 2021-03-09 | 2024-02-29 | イーライ リリー アンド カンパニー | パーキンソン病の進行を減速させるためのメビダレン及び他のｄ１ポジティブアロステリック調節因子の使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| CA3175785A1 (fr) * | 2014-09-04 | 2016-03-10 | Intrance International Ab | Compositions pharmaceutiques comprenant de la levodopa, un inhibiteur de la dopamine decarboxylase et un inhibiteur de la comt, et leur procede d'administration |
| AR106332A1 (es) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona |
-
2019
- 2019-12-16 SG SG11202106595VA patent/SG11202106595VA/en unknown
- 2019-12-16 LT LTEPPCT/US2019/066465T patent/LT3897578T/lt unknown
- 2019-12-16 TW TW108146071A patent/TWI831896B/zh active
- 2019-12-16 MA MA71651A patent/MA71651A/fr unknown
- 2019-12-16 UA UAA202103923A patent/UA126882C2/uk unknown
- 2019-12-16 WO PCT/US2019/066465 patent/WO2020131671A1/fr not_active Ceased
- 2019-12-16 EP EP24180893.0A patent/EP4417258A3/fr active Pending
- 2019-12-16 KR KR1020217022499A patent/KR20210111783A/ko not_active Ceased
- 2019-12-16 MX MX2021007442A patent/MX2021007442A/es unknown
- 2019-12-16 KR KR1020257015518A patent/KR20250069706A/ko active Pending
- 2019-12-16 MA MA54530A patent/MA54530B1/fr unknown
- 2019-12-16 TW TW112133925A patent/TWI892226B/zh active
- 2019-12-16 MD MDE20211050T patent/MD3897578T2/ro unknown
- 2019-12-16 PT PT198368847T patent/PT3897578T/pt unknown
- 2019-12-16 PL PL19836884.7T patent/PL3897578T3/pl unknown
- 2019-12-16 DK DK19836884.7T patent/DK3897578T3/da active
- 2019-12-16 HU HUE19836884A patent/HUE069782T2/hu unknown
- 2019-12-16 CA CA3124416A patent/CA3124416C/fr active Active
- 2019-12-16 AU AU2019402087A patent/AU2019402087B2/en active Active
- 2019-12-16 RS RS20241415A patent/RS66337B1/sr unknown
- 2019-12-16 ES ES19836884T patent/ES3004543T3/es active Active
- 2019-12-16 JP JP2021535892A patent/JP2022514659A/ja not_active Withdrawn
- 2019-12-16 FI FIEP19836884.7T patent/FI3897578T3/fi active
- 2019-12-16 CN CN201980089891.3A patent/CN113347961A/zh active Pending
- 2019-12-16 HR HRP20241778TT patent/HRP20241778T1/hr unknown
- 2019-12-16 US US17/416,320 patent/US20220062265A1/en active Pending
- 2019-12-16 SI SI201930869T patent/SI3897578T1/sl unknown
- 2019-12-16 BR BR112021012102-1A patent/BR112021012102A2/pt unknown
- 2019-12-16 EP EP19836884.7A patent/EP3897578B1/fr active Active
- 2019-12-16 MY MYPI2021003450A patent/MY209406A/en unknown
-
2021
- 2021-06-18 IL IL284175A patent/IL284175A/en unknown
- 2021-06-28 ZA ZA2021/04466A patent/ZA202104466B/en unknown
-
2023
- 2023-01-24 JP JP2023008488A patent/JP2023055770A/ja active Pending
-
2025
- 2025-08-06 JP JP2025131198A patent/JP2025163202A/ja active Pending
- 2025-08-06 JP JP2025131199A patent/JP2025163203A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54530B1 (fr) | Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques | |
| MA54231A (fr) | Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine | |
| MA46018A (fr) | Activateurs d'édition du génome | |
| MA51568A (fr) | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central | |
| MA51520A (fr) | Dérivés de 1,3,4,5-tétrahydro-2h-pyrido[4,3-b]indole pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de tau comme la maladie d'alzheimer | |
| MA30089B1 (fr) | (arylsulfonyl)-pyrasolopiperidines | |
| MA53500A (fr) | Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques | |
| EA201290764A1 (ru) | Способы и композиции для улучшения когнитивной функции | |
| MX388726B (es) | Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo. | |
| MA43113A (fr) | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci | |
| MA30037B1 (fr) | Compositions et procedes destines au traitement des troubles du snc | |
| EP4216946A4 (fr) | Composés pharmaceutiques pour le traitement de troubles à médiation par complément | |
| IL255782A (en) | Extended release pharmaceutical compositions of levetiracetam | |
| EA201390712A1 (ru) | Производные пиридазина, композиции и способы лечения когнитивного нарушения | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| JP2018516906A5 (fr) | ||
| EA201890090A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| MA53739A (fr) | Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés | |
| MA46611B1 (fr) | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs | |
| GB2557471A (en) | Arginine silicate inositol for improving cognitive function | |
| MX2023000405A (es) | Combinaciones de agonistas del receptor a del acido gamma aminobutirico (gabaa) alfa 5 e inhibidores de la glicoproteina de vesicula sinaptica 2a (sv2a) y metodos de uso en el tratamiento del deterioro cognitivo. | |
| MA56540A (fr) | Procédés et intermédiaires pour la préparation de 2-(2,6-dichlorophényle))-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl-3,4-dihydroisoquinolin-2(1)-yl]éthénone | |
| EA202191715A1 (ru) | Режимы дозирования для использования ly3154207 при лечении дофаминергических нарушений цнс | |
| NZ778221B2 (en) | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |